Drugmakers Question FDA Thinking on New Inspection Powers
Drug Industry Daily
Oct. 4, 2013| Vol. 12 No. 193
The FDA’s interpretation of what constitutes delaying or denying an inspection is far too subjective, and highlights the need for an appeals process for pharma companies flagged as obstructionist, drugmakers say in comments.
This article is viewable by subscribers only. To view this article, please select an option below.